Justin Stebbing

Add links
From Wikipedia, the free encyclopedia
Justin Stebbing

Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene,[1] a visiting Professor of Cancer Medicine and Oncology at Imperial College, London [2] and a Professor of Biomedical Sciences at ARU, Cambridge.[3] He works at the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely.[4] He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals.

Early life and education[edit]

He graduated with a first class degree from Trinity College, Oxford. After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital on the Longcope team in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Justin's original PhD research investigated the interplay between the immune system and cancer including the role of viruses here.[5][6] In 2007 he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London.[7] In 2011, the National Institute for Health and Care Research (NIHR) awarded Justin Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and new targeted precision medicine approaches.[8]

Cancer research[edit]

He has published over 700 peer-reviewed papers in academic journals[9] and has an h-index of 89 according to Google Scholar.[10] He is Editor-in-Chief of the journal Oncogene[11] a Fellow of the Royal College of Physicians[12] the American Society for Clinical Investigation[13] and the Royal College of Pathologists.[14] The charity Action Against Cancer was set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.[15] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.[16][17][18][19] He has undertaken extensive work on biosimilars,[20] cheaper versions of expensive biologic drugs designed to democratise access to these around the world, now with long term outcomes data.[21] In 2023, new data his team published has shown the importance of genomics in normal tissues, and the mechanism by which both age and pregnancy contribute to changes in DNA, some of which can lead to breast cancer,[22] highlighted as one of Nature Communications most important papers,[23] and widely publicised in the news.[24][25]

COVID-19 research[edit]

Professor Justin Stebbing made a global contribution to millions of lives by leveraging artificial intelligence (AI) to identify baricitinib as a drug for the treatment of COVID-19 in early 2020, papers in the Lancet and Lancet Infectious Diseases that are now cited thousands of times.[26][27] Uniquely this has both antiviral and anti-cytokine properties as confirmed by subsequent mechanistic laboratory work.[28][29][30] He led many of the global studies that showed that the drug reduced mortality in COVID-19 hospitalized patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone.[31] Much of this work is summarized by editorials he wrote in the New England Journal of Medicine and Lancet Respiratory Medicine which describe this further.[32][33] The book, ‘Witness to COVID, 2020’ [34][35] was written by Justin Stebbing describing its discovery, trials, studies and approval,[36] also highlighted in news outlets such as The New York Times.[37] In January 2022, following Professor Stebbing's pivotal original papers and the subsequent global trials, the World Health Organization placed baricitinib at the top of its evidence base to treat COVID-19, giving it its highest recommendation.[38][39] This has also been made free to countries around the world in charitable shipments[40] as they have struggled with numbers of patients, considering it is a simple once daily tablet with few drug-drug interactions, side effects, has dose flexibility, a short half-life and is cheap, as his work here has outlined.[41][42] Based on Prof Stebbing's original AI hypothesis, following the success of the clinical trials including RECOVERY, the US FDA gave baricitinib an unconditional approval, the first immunomodulatory treatment for COVID-19. Separately, Professor Stebbing was also investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients with no further options who he had cared for between 2014 and 2017 and he returned to unrestricted practice in October 2022 after a suspension earlier that year. In 2024 he was co-senior author on a paper in Nature Communications[43] using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic, as publicised.[44]

Other work[edit]

Professor Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.[45] He has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust.[46] He is actively engaged with a number of companies, is senior oncology advisor to Clinical ink[47] and chairs the ZephyrAI scientific advisory board.[48] He is senior VP of clinical strategy and innovation[49] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.

References[edit]

  1. ^ "About the Editors | Oncogene". www.nature.com. Retrieved 2022-10-29.
  2. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2022-10-29.
  3. ^ "Professor Justin Stebbing - ARU". aru.ac.uk. Retrieved 2022-11-30.
  4. ^ "Professor Justin Stebbing". Phoenix Hospital Group. Retrieved 2022-10-29.
  5. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (2004-04-29). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. ISSN 0028-4793. PMID 15115833.
  6. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  7. ^ "PWP Messages".
  8. ^ "Current NIHR Research Professors". www.nihr.ac.uk. Retrieved 2024-01-07.
  9. ^ "stebbing j - Search Results - PubMed". PubMed. Retrieved 2024-01-07.
  10. ^ "Justin Stebbing". scholar.google.com. Retrieved 2024-01-07.
  11. ^ "About the Editors". Oncogene.
  12. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  13. ^ "The American Society for Clinical Investigation".
  14. ^ "Honours and Memberships - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2024-01-07.
  15. ^ "Home | Action Against Cancer". www.aacancer.org. Retrieved 28 March 2023.
  16. ^ Giamas, Georgios; Filipović, Aleksandra; Jacob, Jimmy; Messier, Walter; Zhang, Hua; Yang, Dongyun; Zhang, Wu; Shifa, Belul Assefa; Photiou, Andrew; Tralau-Stewart, Cathy; Castellano, Leandro; Green, Andrew R.; Coombes, R. Charles; Ellis, Ian O.; Ali, Simak; Lenz, Heinz-Josef; Stebbing, Justin (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.[non-primary source needed]
  17. ^ Castellano, Leandro; Giamas, Georgios; Jacob, Jimmy; Coombes, R. Charles; Lucchesi, Walter; Thiruchelvam, Paul; Barton, Geraint; Jiao, Long R.; Wait, Robin; Waxman, Jonathan; Hannon, Gregory J.; Stebbing, Justin (21 August 2009). "The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response". Proceedings of the National Academy of Sciences. 106 (37): 15732–15737. Bibcode:2009PNAS..10615732C. doi:10.1073/pnas.0906947106. PMC 2747188. PMID 19706389.[non-primary source needed]
  18. ^ Bower, M.; Nelson, M.; Young, A.M.; Thirlwell, C.; Newsom-Davis, T.; Mandalia, S.; Dhillon, T.; Holmes, P.; Gazzard, B.G.; Stebbing, J. (1 August 2005). "Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma". Journal of Clinical Oncology. 23 (22): 5224–5228. doi:10.1200/JCO.2005.14.597. PMID 16051964.[non-primary source needed]
  19. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (29 April 2004). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. PMID 15115833.[non-primary source needed]
  20. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  21. ^ Stebbing, Justin; Baranau, Yauheni; Baryash, Valery; Moiseyenko, Vladimir; Boliukh, Dmytro; Antone, Nicoleta; Manikhas, Alexey; Chornobai, Anatolii; Park, Taehong; Baek, Eric Hyungseok; Lee, Jaeyong; Choi, Jiin; Kim, Nahyun; Ahn, Keumyoung; Lee, Sang Joon (2023). "Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial". Biodrugs. 37 (3): 433–440. doi:10.1007/s40259-023-00582-w. ISSN 1173-8804. PMC 10195725. PMID 36881323.
  22. ^ Cereser, Biancastella; Yiu, Angela; Tabassum, Neha; Del Bel Belluz, Lisa; Zagorac, Sladjana; Ancheta, Kenneth Russell Zapanta; Zhong, Rongrong; Miere, Cristian; Jeffries-Jones, Alicia Rose; Moderau, Nina; Werner, Benjamin; Stebbing, Justin (2023-09-06). "The mutational landscape of the adult healthy parous and nulliparous human breast". Nature Communications. 14 (1): 5136. Bibcode:2023NatCo..14.5136C. doi:10.1038/s41467-023-40608-z. hdl:10044/1/105809. ISSN 2041-1723. PMC 10482899. PMID 37673861.
  23. ^ "Genetics, genomics and epigenetics". Nature. 2021-01-26. Retrieved 2024-01-07.
  24. ^ Knapton, Sarah (2023-09-06). "Bodily changes in pregnancy raise breast cancer risk for older mothers". The Telegraph. ISSN 0307-1235. Retrieved 2024-01-07.
  25. ^ "'Older mothers at risk' as breast growth in pregnancy can increase cancer risk". Yahoo News. 2023-09-07. Retrieved 2024-01-07.
  26. ^ Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin (15 February 2020). "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet. 395 (10223): e30–e31. doi:10.1016/S0140-6736(20)30304-4. PMC 7137985. PMID 32032529.[non-primary source needed]
  27. ^ "Redirecting". linkinghub.elsevier.com. Retrieved 2024-01-07.
  28. ^ "COVID-19 survival among elderly patients could be improved by arthritis drug | Imperial News | Imperial College London". Imperial News. 2020-11-13. Retrieved 2024-01-07.
  29. ^ Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J; Monteil, Vanessa; Lauschke, Volker M; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A Ross; Nickoloff, Brian J (2020-08-07). "Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID -19 patients". EMBO Molecular Medicine. 12 (8): e12697. doi:10.15252/emmm.202012697. ISSN 1757-4676. PMC 7300657. PMID 32473600.
  30. ^ Stebbing, Justin; Sánchez Nievas, Ginés; Falcone, Marco; Youhanna, Sonia; Richardson, Peter; Ottaviani, Silvia; Shen, Joanne X.; Sommerauer, Christian; Tiseo, Giusy; Ghiadoni, Lorenzo; Virdis, Agostino; Monzani, Fabio; Rizos, Luis Romero; Forfori, Francesco; Avendaño Céspedes, Almudena (2021-01-01). "JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality". Science Advances. 7 (1): eabe4724. Bibcode:2021SciA....7.4724S. doi:10.1126/sciadv.abe4724. ISSN 2375-2548. PMC 7775747. PMID 33187978.
  31. ^ "Olumiant EUA FAQs | FDA". www.fda.gov. Retrieved 2024-02-14.
  32. ^ Stebbing, Justin; Lauschke, Volker M. (2021-07-29). "JAK Inhibitors — More Than Just Glucocorticoids". New England Journal of Medicine. 385 (5): 463–465. doi:10.1056/NEJMe2108667. ISSN 0028-4793. PMC 8362590. PMID 34320294.
  33. ^ Kalil, Andre C; Stebbing, Justin (December 2021). "Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial". The Lancet. Respiratory Medicine. 9 (12): 1349–1351. doi:10.1016/S2213-2600(21)00358-1. ISSN 2213-2600. PMC 8409093. PMID 34480862.
  34. ^ Stebbing, Justin (15 November 2021). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 9781398112674.
  35. ^ Stebbing, Justin (2021-11-15). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. Amberley. ISBN 978-1-3981-1267-4.
  36. ^ Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books. ASIN 1398112674.
  37. ^ Metz, Cade (2020-04-30). "How A.I. Steered Doctors Toward a Possible Coronavirus Treatment". The New York Times. ISSN 0362-4331. Retrieved 2024-01-07.
  38. ^ Agarwal, Arnav; Hunt, Beverley J.; Stegemann, Miriam; Rochwerg, Bram; Lamontagne, François; Siemieniuk, Reed AC; Agoritsas, Thomas; Askie, Lisa; Lytvyn, Lyubov; Leo, Yee-Sin; Macdonald, Helen; Zeng, Linan; Alhadyan, Ahmed; Muna, Al-Maslamani; Amin, Wagdy (2020-09-04). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. ISSN 1756-1833. PMID 32887691.
  39. ^ "WHO recommends two new drugs to treat COVID-19". www.who.int. Retrieved 2024-01-07.
  40. ^ Company, Eli Lilly and. "Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements". www.prnewswire.com (Press release). Retrieved 2024-02-14.
  41. ^ https://www.benevolent.com/news/who-recommends-baricitnib-for-hospitalised-patients-with-covid-19
  42. ^ "Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements" (Press release). Eli Lilly. 4 May 2021.
  43. ^ Hammond, Terese C.; Purbhoo, Marco A.; Kadel, Sapana; Ritz, Jerome; Nikiforow, Sarah; Daley, Heather; Shaw, Kit; van Besien, Koen; Gomez-Arteaga, Alexandra; Stevens, Don; Ortuzar, Waldo; Michelet, Xavier; Smith, Rachel; Moskowitz, Darrian; Masakayan, Reed (2024-02-06). "A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome". Nature Communications. 15 (1): 974. Bibcode:2024NatCo..15..974H. doi:10.1038/s41467-024-44905-z. ISSN 2041-1723. PMC 10847411. PMID 38321023.
  44. ^ Reporters, Telegraph (2024-02-07). "New cancer drug could improve prognosis for Covid patients". The Telegraph. ISSN 0307-1235. Retrieved 2024-02-14.
  45. ^ Corp, Equilibre Biopharmaceuticals. "Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy". www.prnewswire.com (Press release). Retrieved 2024-01-07.
  46. ^ "BB Healthcare Trust delivers as it comfortably beats its benchmark". Proactiveinvestors UK. 2018-02-14. Retrieved 2024-01-07.
  47. ^ "Justin Stebbing, PhD, M.D. | Expert Advisor". Clinical ink. Retrieved 2024-01-07.
  48. ^ "Zephyr AI Announces Formation of Scientific and Medical Advisory Board". www.businesswire.com. 2022-12-05. Retrieved 2024-01-07.
  49. ^ "Our Company". gravitoncorp.com. Retrieved 2024-02-14.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Justin_Stebbing&oldid=1217396305"